CFO-linked entities at Royalty Pharma (RPRX) sell 34,791 Class A shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Royalty Pharma plc insider reporting shows entities associated with EVP & CFO Terrance P. Coyne selling Class A Ordinary Shares of the company. On the reported date, TPC RP 2021, LLC and TPC RP EPA1 LLC together sold 34,791 shares in open-market transactions at a weighted average price of $45.3165 per share.
The filing notes these transactions were carried out under a pre-established Rule 10b5-1 trading plan adopted on August 8, 2025, which automates sales based on preset instructions. A footnote explains the reported sale price is an average, with individual trades executed between $44.97 and $45.60 per share.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 34,791 shares ($1,576,606)
Net Sell
6 txns
Insider
Coyne Terrance P.
Role
EVP & CFO
Sold
34,791 shs ($1.58M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Class A Ordinary Shares | 32,916 | $45.3165 | $1.49M |
| Sale | Class A Ordinary Shares | 1,875 | $45.3165 | $85K |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Class A Ordinary Shares — 131,664 shares (Indirect, By TPC RP 2021, LLC);
Class A Ordinary Shares — 1,500 shares (Direct)
Footnotes (1)
- All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.97 to $45.60 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.